Ambrx Biopharma PE Ratio 2020-2021 | AMAM

Current and historical p/e ratio for Ambrx Biopharma (AMAM) from 2020 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Ambrx Biopharma PE ratio as of December 07, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Ambrx Biopharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-12-06 8.11 inf
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.322B $0.014B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71